Boehringer Ingelheim GmbH:企業の戦略的SWOT分析

◆英語タイトル:Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review
◆商品コード:DATA904C2742
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥16,875見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥50,625見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Boehringer Ingelheim GmbH – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Boehringer Ingelheim GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG is a pharmaceutical company that conducts research, development, manufacture and sale of pharmaceuticals. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. It operates facilities for manufacture pharmaceuticals, chemical active substances, and medical products. Boehringer operates globally through affiliates and is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Boehringer Ingelheim GmbH Key Recent Developments

Aug 07,2018: Boehringer forms new alliance to develop gene therapy
Aug 06,2018: Researchers partner with industry to develop ground-breaking gene therapy for CF
Aug 02,2018: Boehringer Ingelheim launches the initiative In Reach Africa to address key healthcare infrastructure and access priorities across Africa
Aug 01,2018: Boehringer Ingelheim achieves modest growth in the first half of 2018
Jul 14,2018: Boehringer Ingelheim unveils 15 new medicines

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Boehringer Ingelheim GmbH – Key Facts 6
Boehringer Ingelheim GmbH – Key Employees 7
Boehringer Ingelheim GmbH – Key Employee Biographies 8
Boehringer Ingelheim GmbH – Major Products and Services 9
Boehringer Ingelheim GmbH – History 11
Boehringer Ingelheim GmbH – Company Statement 23
Boehringer Ingelheim GmbH – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Section 2 – Company Analysis 26
Company Overview 26
Boehringer Ingelheim GmbH – Business Description 27
Business Segment: Animal Health 27
Overview 27
Performance 27
Key Stats 27
Business Segment: Biopharmaceuticals 27
Overview 27
Performance 28
Key Stats 28
Business Segment: Discontinued Operations 28
Performance 28
Business Segment: Human Pharmaceuticals 28
Overview 28
Performance 28
Business Segment: Industrial Customers and Other Sales 29
Overview 29
Performance 29
Geographical Segment: Americas 29
Performance 29
Geographical Segment: Asia/Australia/Africa 29
Performance 29
Geographical Segment: Europe 29
Performance 29
R&D Overview 29
Boehringer Ingelheim GmbH – Corporate Strategy 30
Boehringer Ingelheim GmbH – SWOT Analysis 31
SWOT Analysis – Overview 31
Boehringer Ingelheim GmbH – Strengths 31
Boehringer Ingelheim GmbH – Weaknesses 32
Boehringer Ingelheim GmbH – Opportunities 33
Boehringer Ingelheim GmbH – Threats 34
Boehringer Ingelheim GmbH – Key Competitors 35
Section 3 – Company’s Lifesciences Financial Deals and Alliances 36
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37
Boehringer Ingelheim GmbH, Recent Deals Summary 38
Section 4 – Company’s Recent Developments 39
Aug 06, 2018: Researchers partner with industry to develop ground-breaking gene therapy for CF 39
Aug 02, 2018: Boehringer Ingelheim launches the initiative In Reach Africa to address key healthcare infrastructure and access priorities across Africa 40
Aug 01, 2018: Boehringer Ingelheim achieves modest growth in the first half of 2018 41
Jul 11, 2018: Boehringer Ingelheim acquires MabVax’s programme for solid tumours 42
Jul 04, 2018: Boehringer Ingelheim extends “one-stop-shop” service with new fill & finish capabilities in China 43
May 23, 2018: Big Pharma CMOs Win for Biologic API and Alcami Scores Highest for Biologic Drug Product 44
Apr 25, 2018: Boehringer Ingelheim has a very successful 2017 financial year 45
Apr 25, 2018: Boehringer Ingelheim RD pushes to transcend disease boundaries 46
Apr 24, 2018: Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement 49
Apr 11, 2018: Investment Of 65 Million Euro In Avian Vaccines In France 50
Section 5 – Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Boehringer Ingelheim GmbH, Key Facts 6
Boehringer Ingelheim GmbH, Key Employees 7
Boehringer Ingelheim GmbH, Key Employee Biographies 8
Boehringer Ingelheim GmbH, Major Products and Services 9
Boehringer Ingelheim GmbH, History 11
Boehringer Ingelheim GmbH, Other Locations 24
Boehringer Ingelheim GmbH, Subsidiaries 24
Boehringer Ingelheim GmbH, Key Competitors 35
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37
Boehringer Ingelheim GmbH, Recent Deals Summary 38

List of Figures
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 37

★海外企業調査レポート[Boehringer Ingelheim GmbH:企業の戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aslan Pharmaceuticals Pte Ltd:企業のM&A・事業提携・投資動向
    Aslan Pharmaceuticals Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Aslan Pharmaceuticals Pte Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Trent Ltd (TRENT):企業の財務・戦略的SWOT分析
    Trent Ltd (TRENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Medicontur Medical Engineering Ltd:製品パイプライン分析
    Summary Medicontur Medical Engineering Ltd (Medicontur) is a developer and manufacturer of intraocular lenses. The company offers hydrophilic and hydrophobic model lenses including monofocal aspheric, toric, and standard monofocal aspheric lenses; preloaded capsular tension rings; PMMA implants; inj …
  • Chesapeake Energy Corporation (CHK):石油・ガス:M&Aディール及び事業提携情報
    Summary Chesapeake Energy Corp (Chesapeake) is an upstream oil and gas company in the US. The company explores for, develops and produces oil and gas from its assets. It has liquid operations in Eagle Ford Shale; the Utica Shale; the Granite Wash, Cleveland, Tonkawa and Mississippian Lime plays in t …
  • MOIL Ltd:企業の戦略・SWOT・財務分析
    MOIL Ltd - Strategy, SWOT and Corporate Finance Report Summary MOIL Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • HTG Molecular Diagnostics Inc (HTGM):製薬・医療:M&Aディール及び事業提携情報
    Summary HTG Molecular Diagnostics Inc (HTG) is a technology company that provides molecular technology solutions. The company provides products such as HTG edge system, HTG edgeseq reagents and HTG edgeseq immuno-oncology biomarker panel assay, among others. It develops assays and reagent systems th …
  • Cox Enterprises Inc:企業の戦略的SWOT分析
    Cox Enterprises Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Tiziana Life Sciences Plc (TILS):企業の財務・戦略的SWOT分析
    Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Zoo Digital Group plc (ZOO):企業の財務・戦略的SWOT分析
    Summary Zoo Digital Group Plc (ZOO) is a technology company that offers localization and media production services. It offers services such as subtitling, captioning, dubbing and digital distribution. The company's activities include providing a range of services to allow television and movie conten …
  • CIMB Group Holdings Bhd:企業の戦略・SWOT・財務情報
    CIMB Group Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary CIMB Group Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Mateon Therapeutics Inc (MATN):企業の財務・戦略的SWOT分析
    Summary Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting age …
  • Advance Syntex Limited (539982):企業の戦略的SWOT分析
    Advance Syntex Limited (539982) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Toyobo Co., Ltd.:企業の戦略・SWOT・財務分析
    Toyobo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyobo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • MilliporeSigma:医療機器:M&Aディール及び事業提携情報
    Summary MilliporeSigma, formerly Sigma-Aldrich Corp, a subsidiary of Merck KGaA is a life sciences and technology company which offers biochemical and organic chemical products, kits and services. Its products and services find application in scientific research including genomic and proteomic resea …
  • Bhansali Engineering Polymers Ltd (BEPL):企業の財務・戦略的SWOT分析
    Summary Bhansali Engineering Polymers Ltd (BEPL), formerly Bhansali Steel Ltd is a petrochemical company that manufactures and markets acrylonitrile butadiene styrene. The company's products include general ABS, extrusion ABS, flame retardant ABS, ABS-GF or SAN-GF, PMMA-ABS, PVC modifier, PC or ABS …
  • Laing O’Rourke Plc:企業の戦略的SWOT分析
    Laing O'Rourke Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Brickell Biotech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Brickell Biotech Inc (Brickell Biotech) is a pharmaceutical company that develops differentiated therapeutics for the treatment of skin diseases. The company offers pipeline product candidates such as BBI-4000, BBI-5000, BBI-2000, BBI-3000 and BBI -6000. Its product candidate BBI-4000 is an …
  • Byco Petroleum Pakistan Ltd (BYCO):企業の財務・戦略的SWOT分析
    Byco Petroleum Pakistan Ltd (BYCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • The Miyazaki Taiyo Bank, Ltd.:企業の戦略・SWOT・財務情報
    The Miyazaki Taiyo Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Miyazaki Taiyo Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Intellipharmaceutics International Inc (IPCI):製薬・医療:M&Aディール及び事業提携情報
    Summary Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral solid dosa …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆